Drug Approval | February 23, 2022
Zydus receives USFDA approval for Dapagliflozin tablets
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad
It is used to control, prevent and normalize the symptoms associated with Alzheimer's disease, attention disorder, bipolar disorder, Parkinson's disease among others
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
He will continue to lead business in LATAM and Asia regions in this new role
Appoints Dr Rafiq Hasan as CEO
he financing was significantly oversubscribed with high demand from both existing and new investors.
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
Subscribe To Our Newsletter & Stay Updated
